Skip to main content
françaisFR
European Commission logo print header

Development and testing of a combined anti-retroviral, immune, and gene therapy for treatment of hiv patients

Objectif

The treatment of HIV patients has been greatly improved by the development overheard. However, despite a strong reduction in the number of virus producing cellsHAART does not fully eradicate the virus, making sustained treatment necessary. In addition, immune function is only partly restored during HAART. Therefore, the focus has recently shifted to supplementing HAART with additional immune therapy. The aim of this project is to develop and test a new protocol for the treatment of HIV patients, based on a combination of anti-retroviral, immune and gene therapies. The main target of this therapy shall be to restore CD4 helper T-cell immune responses. These cells are central immune regulators that largely determine the type and strength of the immune response generated following antigen encounter and thus the efficiency with which a particular infection is controlled by the body.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Contribution de l’UE
Aucune donnée
Adresse
157,Lange Kleiweg 139
2288 GJ RIJSWIJK ZH
Pays-Bas

Voir sur la carte
Coût total
Aucune donnée

Participants (6)

Partager cette page

Télécharger

Dernière mise à jour: 12 Avril 2005

Mon livret

Permalink: https://cordis.europa.eu/project/id/QLK2-CT-2000-01040/fr

European Union, 2024